EMERGING COMPANIES
Scientia’s clients operate in one of the economy’s most complex settings – the life science industry. Scientia Advisors has a deep understanding of how to build successful emerging life science companies.Scientia draws on a full range of industry and functional expertise acquired from over 30 years as corporate strategy consultants to large and small companies around the word. We bring those capabilities to help a business define its options and identify the best direction. An emerging company must prioritize its lines of alternative products through interviewing and surveying customers, clinicians, payers and potential partners.
Our team has worked with dozens of clients backed by top tier venture firms developing growth strategies, operational plans, financing strategies, business development strategies, public relations & communication strategies, positioning, technology assessments, program prioritization, commercialization strategy and valuations.
Scientia has developed strategies leveraging both a macro and micro viewpoint. Our cross section of clients, working with both global and emerging companies allows us to have an unique insight into market forces.
Examples of several of the types of strategies we provide emerging clients:
- Post Investment Growth Strategy
- Program Prioritization
- Market Strategy and Positioning
- Valuation
Pharmacogenetics: Promises and challenges
An industry commentary by Scientia Advisors
Pharmacogenetics (PGx), the application of genetic variation to understand variability in medicine response has been heralded as the facilitator of personalized medicine and targeted therapies that could alter the healthcare landscape.
An industry commentary by Scientia Advisors
Pharmacogenetics (PGx), the application of genetic variation to understand variability in medicine response has been heralded as the facilitator of personalized medicine and targeted therapies that could alter the healthcare landscape.
